These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 35059624)

  • 1. Comparative differential cytotoxicity of clinically used SERMs in human cancer lines of different origin and its predictive molecular docking studies of key target genes involved in cancer progression and treatment responses.
    S L; A S; Dv S; Bs R; R S; Sharaf S; Sa A; G R
    Curr Res Pharmacol Drug Discov; 2022; 3():100080. PubMed ID: 35059624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective estrogen receptor modulators: an update on recent clinical findings.
    Shelly W; Draper MW; Krishnan V; Wong M; Jaffe RB
    Obstet Gynecol Surv; 2008 Mar; 63(3):163-81. PubMed ID: 18279543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonhormonal selective estrogen receptor modulator 1-(2-[4-{(3R,4S)-7-Methoxy-2, 2-dimethyl-3-phenyl-chroman-4yl}phenoxy]ethyl)pyrrolidine hydrochloride (ormeloxifene hydrochloride) for the treatment of breast cancer.
    Pillai LS; Regidi S; Varghese SD; Ravindran S; Maya V; Varghese J; Ramaswami K; Gopimohan R; Gopi M
    Drug Dev Res; 2018 Sep; 79(6):275-286. PubMed ID: 30284735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ormeloxifene on ovariectomy-induced bone resorption, osteoclast differentiation and apoptosis and TGF beta-3 expression.
    Narayana Murthy PS; Sengupta S; Sharma S; Singh MM
    J Steroid Biochem Mol Biol; 2006 Aug; 100(4-5):117-28. PubMed ID: 16797179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SERMs and SERMs with estrogen for postmenopausal osteoporosis.
    Bolognese MA
    Rev Endocr Metab Disord; 2010 Dec; 11(4):253-9. PubMed ID: 20446043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cardiovascular effects of selective estrogen receptor modulators.
    Christodoulakos GE; Lambrinoudaki IV; Botsis DC
    Ann N Y Acad Sci; 2006 Dec; 1092():374-84. PubMed ID: 17308162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell type- and estrogen receptor-subtype specific regulation of selective estrogen receptor modulator regulatory elements.
    Ball LJ; Levy N; Zhao X; Griffin C; Tagliaferri M; Cohen I; Ricke WA; Speed TP; Firestone GL; Leitman DC
    Mol Cell Endocrinol; 2009 Feb; 299(2):204-11. PubMed ID: 19059307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Selective Estrogen Receptor Modulators in Breast Cancer Therapy: An Update.
    Das A; Lavanya KJ; Nandini ; Kaur K; Jaitak V
    Curr Med Chem; 2023; 30(29):3287-3314. PubMed ID: 36201273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis.
    Gennari L
    Drugs Today (Barc); 2006 Jun; 42(6):355-67. PubMed ID: 16845439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.
    Lewis JS; Jordan VC
    Mutat Res; 2005 Dec; 591(1-2):247-63. PubMed ID: 16083919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
    Baumann CK; Castiglione-Gertsch M
    Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of selective estrogen receptor modulators on estrogen-sensitive tissues].
    Jirecek S; Pavo I; Huber JC
    Gynakol Geburtshilfliche Rundsch; 1999; 39(4):184-90. PubMed ID: 10629380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
    Johnston SR
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance.
    Sengupta S; Jordan VC
    Adv Exp Med Biol; 2008; 630():206-19. PubMed ID: 18637493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity.
    Franks LN; Ford BM; Prather PL
    Front Pharmacol; 2016; 7():503. PubMed ID: 28066250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer.
    Peng J; Sengupta S; Jordan VC
    Anticancer Agents Med Chem; 2009 Jun; 9(5):481-99. PubMed ID: 19519291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms of selective estrogen receptor modulator (SERM) action.
    Dutertre M; Smith CL
    J Pharmacol Exp Ther; 2000 Nov; 295(2):431-7. PubMed ID: 11046073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of raloxifene, estradiol-17β, dl-ormeloxifene and levormeloxifene on thrombin activity.
    Surin WR; Bhalla H; Kuriakose GC; Singh MM
    J Basic Clin Physiol Pharmacol; 2014 Jan; ():1-8. PubMed ID: 24468615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development.
    Pinkerton JV; Goldstein SR
    Menopause; 2010; 17(3):642-53. PubMed ID: 20107426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogens and SERMs in coronary heart disease.
    Regitz-Zagrosek V; Wintermantel TM; Schubert C
    Curr Opin Pharmacol; 2007 Apr; 7(2):130-9. PubMed ID: 17317318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.